Three key components to scaling quickly—while maintaining purpose.
Dan Asch
Advertisement
Vice President, Oncology Franchise, Boehringer Ingelheim
Articles by Dan Asch
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
3
Merck to Acquire Cidara for $9.2 Billion
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
